Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

poster

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

By natalia / 11/2018

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

By Graviton / 01/2018

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

By Graviton / 10/2017

AASLD

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

By Graviton / 10/2017

AASLD

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

By Graviton / 04/2017

EASL International Liver Congress

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

By Graviton / 12/2016

San Antonio Breast Cancer Symposium

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

By Graviton / 11/2016

AASLD The Liver Meeting

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

By Graviton / 11/2016

NCRI Cancer Conference

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

By Graviton / 06/2016

ASCO Annual Meeting

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

By Graviton / 04/2016

AACR Annual Meeting

Post pagination

← Previous 1 2 3 4 5 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top